Officials at Siemens are contemplating whether to retain the majority ownership in Siemens Healthineers (XETRA: SHL.DE), their former medical technology division. The focus is on examining the financial prospects for Siemens in the healthcare industry and deciding the significance of Healthineers as an asset, as explained by Siemens CFO Ralf Thomas in an article by the Handelsblatt newspaper in Germany that was released today. It is anticipated that these considerations will be concluded by a capital market event at the end of 2025.
Currently, Siemens possesses over 75% ownership of Siemens Healthineers, which became an independent entity from its parent company in 2017. According to Handelsblatt, this figure could decrease to 70% following Siemens’ upcoming $10.6 billion purchase of the U.S.-based software company Altair.
Shares of SHL.DE saw a decline, falling nearly 2% to €51.20 each by today’s close of trading in Frankfurt.
Based in Erlangen, Germany, Siemens Healthineers is ranked as the third-largest medical device company globally, as stated in our latest annual Medtech Big 100 report. Their revenue experienced an increase of just over 3%, reaching €22.4 billion during the most recent fiscal year which concluded on September 30. The company’s workforce expanded to 72,000 employees.
Siemens Healthineers CEO Bernd Montag mentioned in November: “We met our objectives for the fiscal year with a very strong fourth quarter, in spite of the present market challenges in China. This highlights the core robustness of our company and the efforts of the entire Healthineers team. We intend to maintain this drive into the 2025 financial year.”